久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

麗珠( Livzon)  
麗珠集團創建于1985年1月,當時利用特區的地緣和政策優勢，積極開展進出口貿易，不斷發展壯大；在“科技興企”方針指導下，集團開發出以“麗珠得樂”為代表的一系列拳頭產品，以產品的高科技含量和有效的推廣和銷售方式，迅速占領市場，取得良好的經濟效益，使麗珠進入高速發展的軌道。

1993年麗珠成為國內首家股A、B上市的公眾公司。

自2002年起公司進入了第二次創業階段。集團在以企業家朱保國為首的董事會的領導下，規劃了五年內的發展前景，全面實施規范化的流程管理，精益生產，質量第一，產品成為醫患人員信得過的知名大品牌，實現了企業的健康發展。

經過22年努力，麗珠集團已經成為集醫藥產品科研、開發、生產、銷售于一體的綜合性、高新技術型制藥企業集團，在處方藥的生產與銷售領域具有突出優勢，麗珠集團目前在產品種300余個，類別涉及化學藥品、生化藥品、生物工程藥品、微生態制劑、中成藥、診斷試劑等，產品領域涉及消化道、心腦血管、抗感染、生殖內分泌等領域，藥物制劑的主要品牌有麗珠得樂系列、抗病毒顆粒、參芪扶正注射液、腦力隆、麗珠威，以及麗珠腸樂、前列安栓、麗珠賽樂、麗珠廣樂、利脈膠囊等重點品種；另外還擁有抗生素、他汀類及氨基糖苷類原料藥等大型生產基地。

麗珠集團致力于人類生命常青的事業，未來五年的發展戰略目標已經明確：在2010年前進入中國制藥工業企業前五名。

Livzon Pharmaceutical Group Inc., founded in the year of 1985, has already established itself as one of the leading pharmaceutical company in China. In 1993, Livzon became the first local pharmaceutical company to list both A and B shares, with multifold turnover in development, manufacture, and marketing of diversified pharmaceutical products. After a consistent growth, it possesses a total capital of ￡¤2.2 billion RMB inclusive of 24 controlled subsidiaries and joint ventures.
With 9 affiliated plants equipped by advanced facilities, the dynamic production chain efficiently operates to manufacture APIs, finished dosage forms, diagnostic agents and bioactive material, characterized by know-how of fermentation, synthesis, gene recombination, biological extraction, and traditional Chinese medicines, with more than 300 items therapeutically grouped as gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents. Meanwhile, Livzon possesses 4 Production Bases as leading manufacturer of specialist APIs such as fermented antibiotics, sterile cephalosporins, carbapenems, and hypolipemic "Statins".
Livzon's strong foundation lies in quality, and there are 38 production lines in compliance with WHO GMP requirements, including some DMFs and EDMFs documentation, as well as USA FDA inspection, COS and COSHER approvals. Benefited from the regulatory compliance, an extensive overseas market is under robust development, with prosperous vision in Canada, Japan, Middle East, South Africa, South East Asia, and West Europe.
Livzon's core competence has been reinforced by its 3 R& D Centers with vigorous activities in developing innovative technology and products. Meanwhile, Livzon has pioneered the international Licensee-Agreement for developing and marketing patented medicines in China by simultaneous or even prior timeline with overseas counterparts. Livzon has also maintained a superior position in Chinese medicine market, guaranteed by its competent sales force and large distribution network all over the country.
Livzon is striving not only to stand among the top pharmaceutical companies in China, but establish itself a reliable partner for a number of world's leading pharmaceutical companies.